COVID-19 redux: clinical, virologic, and immunologic evaluation of clinical rebound after nirmatrelvir/ritonavir

Brian P Epling; Joseph M Rocco; Kristin L Boswell; Elizabeth Laidlaw; Frances Galindo; Anela Kellogg; Sanchita Das; Allison Roder; Elodie Ghedin; Allie Kreitman; Robin L Dewar; Sophie E M Kelly; Heather Kalish; Tauseef Rehman; Jeroen Highbarger; Adam Rupert; Gregory Kocher; Michael R Holbrook; Andrea Lisco; Maura Manion; Richard A Koup; Irini Sereti

doi:10.1101/2022.06.16.22276392

COVID-19 redux: clinical, virologic, and immunologic evaluation of clinical rebound after nirmatrelvir/ritonavir

medRxiv [Preprint]. 2022 Jun 17:2022.06.16.22276392. doi: 10.1101/2022.06.16.22276392.

Authors

Brian P Epling¹, Joseph M Rocco¹, Kristin L Boswell², Elizabeth Laidlaw¹, Frances Galindo¹, Anela Kellogg³, Sanchita Das⁴, Allison Roder⁵, Elodie Ghedin⁵, Allie Kreitman⁵, Robin L Dewar⁶, Sophie E M Kelly⁷, Heather Kalish⁷, Tauseef Rehman⁶, Jeroen Highbarger⁶, Adam Rupert⁸, Gregory Kocher⁹, Michael R Holbrook⁹, Andrea Lisco¹, Maura Manion¹, Richard A Koup², Irini Sereti¹

Affiliations

¹ Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
² Immunology Laboratory, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
³ Clinical Research Directorate (CRD), Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Frederick, MD, USA.
⁴ Department of Laboratory Medicine, Clinical Center, National Institutes of Health, Bethesda, MD, USA.
⁵ Systems Genomics Section, Laboratory of Parasitic Diseases, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
⁶ Virus Isolation and Serology Laboratory, Frederick National Laboratory, Frederick, MD, USA.
⁷ Trans-NIH Shared Resource on Biomedical Engineering and Physical Science, National Institute of Biomedical Imaging and Bioengineering, National Institutes of Health, Bethesda, MD, USA.
⁸ AIDS Monitoring Laboratory, Frederick National Laboratory, Frederick, MD, USA.
⁹ Integrated Research Facility at Fort Detrick, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Frederick, MD, USA.

Abstract

Clinical rebound of COVID-19 after nirmatrelvir/ritonavir treatment has been reported. We performed clinical, virologic, and immune measurements in seven patients with symptomatic rebound, six after nirmatrelvir/ritonavir treatment and one without previous treatment. There was no evidence of severe disease or impaired antibody and T-cell responses in people with rebound symptoms.

Publication types

Preprint